Skip to content

Hip Denervation in Juvenile Idiopathic Arthritis With Hip Arthritis

Hip Denervation in Juvenile Idiopathic Arthritis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04775225
Enrollment
120
Registered
2021-03-01
Start date
2021-01-06
Completion date
2021-04-06
Last updated
2023-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Arthritis, Juvenile Idiopathic Arthritis

Brief summary

Patients having juvenile idiopathic arthritis (according to ILAR criteria) with hip arthritis were divided into 3 groups. Group 1 received hip denervation and group 2 controlled and received a subcutaneous injection of saline, and group 3 received intra-articular triamcinolone. Outcome measures included pain, tenderness, range of motion, SOLAR, HARISS score. These outcomes were measured at baseline, 2 weeks, and 16 weeks

Detailed description

The aim of the study is to test the effect of denervation of the active hip in JIA and compare it with a placebo without changing systemic treatment during the study. Outcome measures included pain, range of motion, SOLAR score, and Harris functional score.

Interventions

DRUGLidocaine

denervation of the obturator and femoral genicular branches by Lidocaine 2 %

DRUGPlacebo

an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group

DRUGSteroid

Intra-articular injection of 80mg of triamcinolone

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

double-blinded

Eligibility

Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* patients with JIA with unilateral hip arthritis

Exclusion criteria

* hip involvement due to other causes including * septic arthritis * other connective tissue diseases * Avascular necrosis

Design outcomes

Primary

MeasureTime frameDescription
semiquantitative tenderness scoreBaseline, 2 weeks and 16 weeks0 means no tenderness and 3 means maximum tenderness
Change in SOLAR scoreBaseline, 2 weeks and 16 weeksGSUS. 0 means the least synovitis and the maximum, PDUS, o means no PD and 3 the maximum
Change in visual analogue scaleBaseline, 2 weeks and 16 weeksa scale from 0-100 will be used 0 means no pain 100 means the maximum pain
Change in range of motionBaseline, 2 weeks and 16 weeksflexion, internal rotation, external rotation range will be calculated
Change in Harris functional scoreBaseline, 2 weeks and 16 weeks100 means best results and 0 means worst results

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026